← GLP-1

Version 2

Nov 10, 2026. Compare with the current version · Version history

GLP-1 (glucagon-like peptide-1) is a hormone made mainly in the gut and brain that boosts insulin release after meals and curbs appetite; drugs that mimic it, called GLP-1 receptor agonists, are used to treat type 2 diabetes and obesity.

What GLP-1 is

GLP-1 is a peptide, a short chain of amino acids. It is cut from a larger precursor protein, preproglucagon, which is also the source of the hormone glucagon. A 2019 review in Molecular Metabolism, written by 25 researchers in the field, notes that the precursor is expressed in pancreatic α-cells, in enteroendocrine L-cells throughout the gut, and in neurons of the brainstem's nucleus tractus solitarii, which are the primary source of endogenous GLP-1 in the brain. The L-cells line the intestine and release GLP-1 in direct response to luminal nutrients, meaning food passing through the gut.

GLP-1 is an incretin: a gut hormone that raises insulin secretion when sugar arrives by mouth. The idea is older than the hormone. The same review recounts that in 1906 Benjamin Moore reported easing the sugar in diabetic patients' urine with an extract of pig intestine, and that in 1929 Edgard Zunz and Jean LaBarre isolated a gut fraction that decreased blood glucose in experimental animals and named the supposed factor "incretin".

What it does in the body

The 2019 review lists the hormone's main metabolic effects as the glucose-dependent stimulation of insulin secretion, a decrease of gastric emptying (food leaves the stomach more slowly) and inhibition of food intake. It also lowers blood sugar by suppressing glucagon secretion, glucagon being the pancreatic hormone that raises blood sugar. "Glucose-dependent" matters: GLP-1 strengthens insulin release when blood sugar is high, rather than at all times.

It acts by binding the GLP-1 receptor, the target for the hormone in the pancreas, the brain and other tissues. The U.S. prescribing information for the drug Wegovy states that GLP-1 is a physiological regulator of appetite and caloric intake and that the receptor is present in several areas of the brain involved in appetite regulation.

The natural hormone does not last. The review gives its half-life as around 1–2 min, depending on the species: an enzyme in the blood, dipeptidyl peptidase-4 (DPP-4), clips two amino acids off its front end, and the kidneys clear what remains. That short life was the main obstacle to using GLP-1 as a medicine.

Discovery

GLP-1 was found through the genetics of glucagon. According to the Lasker Foundation's account of its 2024 award, Joel Habener's laboratory at Massachusetts General Hospital reported in 1982 that the fish glucagon gene encodes a predicted precursor protein (from the anglerfish) that held a second, glucagon-like sequence; in 1983 Graeme Bell found a similar peptide encoded in the hamster gene and named it GLP-1.

The precursor did not show which form of the peptide was active. Svetlana Mojsov, a peptide chemist, synthesised candidate forms, and in 1986 she, Habener and colleagues reported that a shortened form, GLP-1(7-37), exists in the intestine. In 1987, working with Gordon Weir, they showed it stimulated insulin secretion in rat pancreases, while the longer form was inert even at 10,000-fold higher concentrations. Jens Juul Holst's group in Copenhagen published related findings; the 2019 review lists their 1987 FEBS Letters paper, "Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut", among the founding studies. In 1992 the Boston researchers showed that GLP-1 prompts insulin release and lowers blood glucose in people, and in 1996 Stephen Bloom's group reported that injecting GLP-1 into the brains of rats reduced food intake.

From hormone to medicine

Two routes around the short half-life emerged. One came from a lizard. In 1992 John Eng and colleagues isolated exendin-4, a 39-amino-acid peptide, from the venom of the Gila monster (Heloderma suspectum), published in the Journal of Biological Chemistry. Its first 30 amino acids share ∼53% sequence homology to mammalian GLP-1, and a glycine at the second position protects the peptide from DPP-4-mediated degradation. A synthetic version, exenatide, was developed into the diabetes drugs Byetta and Bydureon.

A Gila monster, a lizard with beaded black and orange skin.
A Gila monster, a lizard with beaded black and orange skin.

Via Wikimedia Commons: Gila monster (Heloderma suspectum) by Theo Kruse / Burgers' Zoo, CC BY-SA 4.0.

The other route was to re-engineer human GLP-1. At Novo Nordisk, Lotte Bjerre Knudsen's team attached a fatty acid so that the drug binds albumin, a protein in the blood. The Lasker Foundation reports that this raised the half-life of the resulting drug, liraglutide, from 1.2 to 13 hours. Liraglutide was approved for type 2 diabetes in Europe in 2009 and the United States in 2010 (as Victoza), and for weight management in the United States in 2014 (as Saxenda). Semaglutide, a later molecule with a half-life of about 165 hours, was approved by the FDA for diabetes in 2017 (Ozempic) and for weight management in 2021 (Wegovy).

A third class of drug, the DPP-4 inhibitors, works the other way round: it blocks the enzyme so that the body's own GLP-1 lasts longer. The 2019 review traces how evidence that blocking DPP-4 preserved intact GLP-1 eventually led to the development of DPP-4 inhibitors for clinical use.

GLP-1 drugs for weight

The FDA's approval letter for Wegovy, dated 4 June 2021, approved it as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 or more, or of 27 or more with at least one weight-related condition such as high blood pressure, type 2 diabetes or abnormal blood fats. Its label states that semaglutide lowers body weight through decreased calorie intake, most likely through effects on appetite.

The Lasker Foundation's 2024 account summarises the trial results: in people with obesity but without diabetes, semaglutide at its weight-management dose produced an average loss of about 15 percent of starting weight; tirzepatide, a related drug from Eli Lilly, was approved for weight loss in 2023 with an average reduction of about 21 percent; and in placebo-controlled trials in people with cardiovascular disease, the drugs reduced the combined rate of cardiovascular death, heart attack or stroke by 20%. Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen received the 2024 Lasker–DeBakey Clinical Medical Research Award for the discovery and development of GLP-1-based drugs that have revolutionized the treatment of obesity.

Tirzepatide and dual-hormone drugs

GLP-1 is not the only incretin. The second, glucose-dependent insulinotropic polypeptide (GIP), is also released by the gut after meals, and drug makers have built molecules that act on both receptors. Tirzepatide, from Eli Lilly, is one: the FDA's announcement of 8 November 2023 describes it as a drug that activates receptors of hormones secreted from the intestine, naming GLP-1 and GIP, to reduce appetite and food intake. It was already sold as Mounjaro for type 2 diabetes when the FDA approved it that day, as Zepbound, for chronic weight management.

The FDA based that approval on two placebo-controlled trials lasting 72 weeks, in which 2,519 people received tirzepatide and 958 received placebo. At the highest approved dose, adults without diabetes lost on average 18% of their body weight compared to those randomized to placebo, and adults with type 2 diabetes lost 12% compared with placebo. The agency added that Zepbound should not be combined with Mounjaro or another GLP-1 receptor agonist.

Heart and kidney outcomes

Weight loss alone does not show that a drug prevents the illnesses linked to obesity, so regulators and researchers have looked for "outcome" trials that count heart attacks, strokes, kidney failure and deaths.

The SELECT trial, published in the New England Journal of Medicine in December 2023, enrolled 17,604 people aged 45 or older who had existing cardiovascular disease and a body-mass index of 27 or more but no diabetes, and gave them weekly semaglutide 2.4 mg or placebo. Over a mean follow-up of 39.8 months, a heart attack, stroke or cardiovascular death occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group, a hazard ratio of 0.80. Side effects led 16.6% of the semaglutide group to stop the drug for good, against 8.2% on placebo. On 8 March 2024 the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight, describing it as the first treatment approved for that purpose specifically in that group.

The FLOW trial tested semaglutide 1.0 mg weekly in 3,533 people with type 2 diabetes and chronic kidney disease. It was stopped early after a planned interim analysis, at a median follow-up of 3.4 years. The risk of a primary-outcome event was 24% lower in the semaglutide group (hazard ratio 0.76), the outcome being a composite of kidney failure, a halving of kidney function, or death from kidney or cardiovascular causes. Death from any cause was 20% lower in the semaglutide group. Both SELECT and FLOW were funded by Novo Nordisk, the maker of semaglutide.

Sleep apnea

On 20 December 2024 the FDA approved tirzepatide (Zepbound) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, calling it the first drug treatment option for certain patients with the condition. In the agency's description, obstructive sleep apnea occurs when the upper airway becomes blocked, causing pauses in breathing during sleep. The approval rested on two 52-week trials in 469 adults without type 2 diabetes, measured by the change in the apnea–hypopnea index, a count of breathing pauses per hour of sleep. The agency wrote that the improvement is likely related to body weight reduction with Zepbound.

Pills

GLP-1 drugs were first given as injections, because peptides are largely broken down in the digestive tract. On 22 December 2025 Novo Nordisk announced US approval of a once-daily semaglutide tablet for weight, the Wegovy pill, as the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The company reported that in its 64-week OASIS 4 trial, participants who kept taking the 25 mg dose lost 16.6% of their body weight on average, and that the approval also covers reducing the risk of major cardiovascular events.

Shortages and compounding

Demand for the drugs outran supply in the United States, and both semaglutide and tirzepatide were placed on the FDA's drug shortage list. Shortage status matters to compounding pharmacies, which mix their own versions of medicines: the FDA explains that once a shortage is resolved it generally considers the drug to be commercially available, which limits what pharmacies may make. The FDA determined that the tirzepatide shortage had been resolved on 2 October 2024, confirmed that decision on 19 December 2024 after re-evaluating it, and on 21 February 2025 determined that the shortage of semaglutide injection products was resolved too, giving compounders grace periods that ran into 2025.

The agency notes that compounded drugs are not FDA approved, and that it had received reports of adverse events, some needing hospital care, tied to dosing errors with compounded semaglutide. As of 31 May 2026, that page counts 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide, figures it says are probably undercounts because many pharmacies are not required to report. On 6 February 2026 the FDA announced its intent to restrict GLP-1 active pharmaceutical ingredients for use in non-approved compounded drugs, and said companies cannot market such products as generic versions of the approved medicines.

Safety

The drugs' best-known side effects are digestive. As of the July 2023 revision, the Wegovy label lists the most common adverse reactions as including nausea, diarrhea, vomiting, constipation, abdominal pain, headache and fatigue, among others. Its warnings include acute pancreatitis and acute gallbladder disease, both seen in clinical trials.

The label also carries a boxed warning about thyroid tumours. It states that in rodents semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors, and that it is unknown whether the drug causes such tumours in humans, because the relevance of the rodent findings has not been determined. On that basis the drug is contraindicated, in the label's words, in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

Global guidance and access

On 1 December 2025 the World Health Organization issued its first guideline on these medicines for obesity. It makes a conditional recommendation that GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity, covering liraglutide, semaglutide and tirzepatide. The recommendation is conditional because of limited data on their long-term efficacy and safety, and a second, also conditional, recommendation on pairing the drugs with intensive behavioural programmes rests on low-certainty evidence.

The same release puts obesity at more than 1 billion people and links it to 3.7 million deaths worldwide in 2024. It notes that in September 2025 WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups, and it warns that, as of December 2025, the medicines were projected to reach fewer than 10% of those who could benefit by 2030.

Micwyn also has an entry on Semaglutide, the most widely known drug of the class.

This entry explains; it is not medical advice. Ask a doctor or pharmacist about your own health.

Sources